Bosentan

Type: Product
Name: Bosentan
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

United Therapeutics Points to Pluristem's PLX-PAD as its Most Transformative Product

Pulmonary arterial hypertension (PAH), a progressive and life threatening illness that regrettably takes a back seat to cardiovascular disease where research is concerned, is incurable and fatal. Characterized by high blood pressure in the arteries of ... [Published BioMedReports - Sep 17 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Sarcoid-Associated Pulmonary Hypertension and Lung Transplant

Cordova FC, D'Alonzo G. Sarcoidosis-associated pulmonary hypertension. Curr Opin Pulm Med 2013;19(5):531–537Battesti JP, Georges R, Basset F, Saumon G. Chronic cor pulmonale in pulmonary sarcoidosis. Thorax 1978;33(1):76–84Głuskowski J, Hawryłkiewicz ... [Published General Medicine eJournal - Sep 15 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Ambrisentan/tadalafil combo could be PAH standard of care

Gilead Sciences and GlaxoSmithKline have caused a stir at the European Respiratory Society meeting in Munich with very impressive late-stage data on a first-line therapy that combines their pulmonary arterial hypertension treatments.The combined treatment ... [Published Pharma Times - Sep 10 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Pulmonary Hypertension With COLD and Pulmonary Fibrosis

Simonneau G, Gatzoulis MA, Adatia I, et al . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol Cardiol 2013; 62:34–41.** This study is a summary on the updated classification of pulmonary hypertension from the recent World Conference ... [Published General Medicine eJournal - Aug 28 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

With An Iffy Non-Oncology Pipeline, Roche Pays Up For InterMune

Summary Roche comes out on top in what was rumored to be a multi-party bidding process for InterMune, agreeing to pay over $8 billion for the developer of Esbriet (for IPF). Even with incremental free cash flow margins above 50%, Roche has to generate ... [Published Seeking Alpha - Aug 27 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

InterMune Wild Ride Set to Pay Off With Drug: Real M

The 14-year roller-coaster ride for InterMune Inc. (ITMN) shareholders may finally be coming to an end.The stock soared above $50 a handful of times since goingpublic in 2000, and fell below $10 just as often as InterMuneworked on developing the first ... [Published Bloomberg - Aug 14 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Industry up in arms against NPPA for bringing 108 non-scheduled drugs under price control

The pharmaceutical industry in the country is up in arms against the recent notification of the National Pharmaceutical Pricing Authority (NPPA) in which the national drug price regulator has brought prices of 108 non-scheduled formulation packs involving ... [Published PharmaBiz - Jul 15 2014]
First reported May 08 2014 - Updated May 08 2014 - 2 reports

Orphan designation: Bosentan, for the: Treatment of systemic sclerosis (scleroderma)

Entities: Bosentan, scleroderma
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

Another REMS Antitrust Lawsuit: Mylan Sues Celgene Over THALOMID and REVLIMID to Obtain Drug Product Sample

By Kurt R. Karst –In a 17-count, 84-page Complaint filed earlier this week in the U.S. District Court for the District of New Jersey, Mylan Pharmaceuticals Inc. (“Mylan”) alleges that Celgene Corporation (“Celgene”) has violated federal and state antitrust ... [Published FDA Law Blog - Apr 04 2014]

More Content

All (10) | News (7) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
United Therapeutics Points to Pluristem's PLX-P... [Published BioMedReports - Sep 17 2014]
Sarcoid-Associated Pulmonary Hypertension and L... [Published General Medicine eJournal - Sep 15 2014]
Ambrisentan/tadalafil combo could be PAH standa... [Published Pharma Times - Sep 10 2014]
Pulmonary Hypertension With COLD and Pulmonary ... [Published General Medicine eJournal - Aug 28 2014]
With An Iffy Non-Oncology Pipeline, Roche Pays ... [Published Seeking Alpha - Aug 27 2014]
InterMune Wild Ride Set to Pay Off With Drug: R... [Published Bloomberg - Aug 14 2014]
Industry up in arms against NPPA for bringing 1... [Published PharmaBiz - Jul 15 2014]
Orphan designation: Bosentan, for the: Treatmen... [Published Orphan designations - May 08 2014]
Orphan designation: Bosentan, for the: Treatmen... [Published Orphan designations - May 08 2014]
Another REMS Antitrust Lawsuit: Mylan Sues Celg... [Published FDA Law Blog - Apr 04 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Orphan designation: Bosentan, for the: Treatmen... [Published Orphan designations - May 08 2014]
Orphan designation: Bosentan, for the: Treatmen... [Published Orphan designations - May 08 2014]
Another REMS Antitrust Lawsuit: Mylan Sues Celg... [Published FDA Law Blog - Apr 04 2014]
By Kurt R. Karst –In a 17-count, 84-page Complaint filed earlier this week in the U.S. District Court for the District of New Jersey, Mylan Pharmaceuticals Inc. (“Mylan”) alleges that Celgene Corporation (“Celgene”) has violated federal and state antitrust ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.